Figure 2.

GLORIOSA enrollment and trial design.

^aTriplet treatment consists of platinum plus chemotherapy plus bevacizumab for planned six cycles (minimum four and maximum eight cycles), including ≥3 cycles of bevacizumab.

^bFRα-high is defined by FRα positivity of ≥75% of tumor membrane staining at ≥2+ intensity (PS2+).

^cFRα-high participants who desire to be treated and followed while on their run-in triplet therapy must sign a run-in consent as part of the main consent form if they meet other study eligibility criteria as assessed by the investigator.

^dMaintenance treatment must begin ≤12 weeks from last dose of triplet therapy and within 30 days of randomization. Treatment continues until PD, unacceptable toxicity, withdrawal of consent, death or study sponsor termination.

^eAIBW, also known as AdjBW, is calculated as IBW (kg) + 0.4 (actual weight – IBW). IBW for females is calculated as 0.9 × height (cm) – 92.

2L: Second-line; AdjBW: Adjusted body weight; AIBW: Adjusted ideal body weight; CR: Complete response; FRα: Folate receptor α; IBW: Ideal body weight; OS: Overall survival; PARPi: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; PS2+: Positive staining 2+; PSOC: Platinum-sensitive ovarian cancer; Q3W: Three-times per week; SD: Stable disease.